These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34002058)

  • 21. Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease.
    Thompson R; Robertson A; Lochmüller H
    Adv Exp Med Biol; 2017; 1031():97-124. PubMed ID: 29214567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common genetic variants contribute to risk of rare severe neurodevelopmental disorders.
    Niemi MEK; Martin HC; Rice DL; Gallone G; Gordon S; Kelemen M; McAloney K; McRae J; Radford EJ; Yu S; Gecz J; Martin NG; Wright CF; Fitzpatrick DR; Firth HV; Hurles ME; Barrett JC
    Nature; 2018 Oct; 562(7726):268-271. PubMed ID: 30258228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
    Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
    Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From the Editor-in-Chief's Desk.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):561. PubMed ID: 28930499
    [No Abstract]   [Full Text] [Related]  

  • 25. Systematic review of the effectiveness of behaviorally-based interventions for sleep problems in people with rare genetic neurodevelopmental disorders.
    McLay L; Roche L; France KG; Blampied NM; Lang R; France M; Busch C
    Sleep Med Rev; 2019 Aug; 46():54-63. PubMed ID: 31060029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A unifying strategy for clinical trials in rare urological malignancy.
    Nicholson S
    Nat Clin Pract Urol; 2008 Dec; 5(12):652-3. PubMed ID: 19015645
    [No Abstract]   [Full Text] [Related]  

  • 27. Design of phase III clinical trials for treatments of orphan retinal diseases: an overview of considerations.
    Hyman L
    Retina; 2005 Dec; 25(8 Suppl):S69-S71. PubMed ID: 16374346
    [No Abstract]   [Full Text] [Related]  

  • 28. Challenges in genetic testing for clinical trials of inherited and orphan retinal diseases.
    Stone EM
    Retina; 2005 Dec; 25(8 Suppl):S72-S73. PubMed ID: 16374347
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial overview: Neurodevelopment Diseases and Neurogenetics pivot towards mechanisms and therapies.
    Geschwind DH; Gleeson JG
    Curr Opin Genet Dev; 2020 Dec; 65():iii-vii. PubMed ID: 33176916
    [No Abstract]   [Full Text] [Related]  

  • 30. Challenges of developing and conducting clinical trials in rare disorders.
    Kempf L; Goldsmith JC; Temple R
    Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.
    de Blieck EA; Augustine EF; Marshall FJ; Adams H; Cialone J; Dure L; Kwon JM; Newhouse N; Rose K; Rothberg PG; Vierhile A; Mink JW;
    Contemp Clin Trials; 2013 Jul; 35(2):48-54. PubMed ID: 23628560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'It would be much easier if we were just quiet and disappeared': Parents silenced in the experience of caring for children with rare diseases.
    Currie G; Szabo J
    Health Expect; 2019 Dec; 22(6):1251-1259. PubMed ID: 31466132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methodology and management of clinical trials with small number of patients for rare diseases].
    Micallef J
    Presse Med; 2012 May; 41 Suppl 1():S32-4. PubMed ID: 22483773
    [No Abstract]   [Full Text] [Related]  

  • 34. Proceedings of the First International Symposium on Translational Clinical Research for Inherited and Orphan Retinal Diseases. November 5-7, 2004. Washington, DC, USA.
    Retina; 2005 Dec; 25(8 Suppl):S1-113. PubMed ID: 16509005
    [No Abstract]   [Full Text] [Related]  

  • 35. Spontaneous remission of cancer - enigma and paradigm.
    Kappauf HW
    Onkologie; 2006 Apr; 29(4):129-30. PubMed ID: 16601368
    [No Abstract]   [Full Text] [Related]  

  • 36. The value of research collaborations and consortia in rare cancers.
    Blay JY; Coindre JM; Ducimetière F; Ray-Coquard I
    Lancet Oncol; 2016 Feb; 17(2):e62-e69. PubMed ID: 26868355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Confronting complexity in the design and conduct of high-risk rare disease clinical trials.
    Stedman HH
    Mol Ther; 2023 May; 31(5):1191-1192. PubMed ID: 37141855
    [No Abstract]   [Full Text] [Related]  

  • 38. The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup.
    Brooks PJ; Ottinger EA; Portero D; Lomash RM; Alimardanov A; Terse P; Xu X; Chandler RJ; Geist Hauserman J; Esposito E; Bönnemann CG; Venditti CP; Austin CP; Pariser A; Lo DC
    Hum Gene Ther; 2020 Oct; 31(19-20):1034-1042. PubMed ID: 32993373
    [No Abstract]   [Full Text] [Related]  

  • 39. Should clinical trials be approached differently for rare cancers?
    Olver I
    Future Oncol; 2016 May; 12(10):1207-9. PubMed ID: 26939845
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.
    Kinder B; McCormack FX
    Lymphat Res Biol; 2010 Mar; 8(1):71-9. PubMed ID: 20235889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.